CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

MESOBLAST LTD

MESO
$2.00BSmall Cap

Next catalyst

Phase 3July 2027

Rexlemestrocel-L + HA mixture

Degenerative Disc Disease

Get an email about MESO's next catalysts

Track MESOBLAST (MESO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 0 past

Phase 3Next

Rexlemestrocel-L + HA mixture Phase 3 Est. Readout (HyaluronicAcid)

July 2027~Rexlemestrocel-L + HA mixture300

Primary completion for Rexlemestrocel-L + HA mixture trial (NCT06325566) in Degenerative Disc Disease

Source

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)Pharmaceuticals🇺🇸North AmericaMELBOURNE, VICTORIA81 employees

Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.

Website
Drug Pipeline

Rexlemestrocel-L

Phase 3

Degenerative Disc Disease

adult human mesenchymal stem cells

Phase 3

Crohn's Disease

Prochymal®

Phase 3

Graft Versus Host Disease

remestemcel-L

Phase 3

Grade B aGVHD

PROCHYMAL adult human mesenchymal stem cells

Phase 3

Crohn's Disease

one MPC expanded cord unit and one unexpanded cord unit

Phase 3

Acute Myelogenous Leukemia

Allogeneic Mesenchymal Precursor Cells (MPCs)

Phase 3

Chronic Heart Failure

Rexlemestrocel-L + HA mixture

Phase 3

Degenerative Disc Disease

Allogeneic Mesenchymal Precursor Cells

Phase 2

Rheumatoid Arthritis

Mesenchymal Precursor Cells (MPC) 12.5 M

Phase 2

Acute Myocardial Infarction

Lumbar Interbody Fusion with NeoFuse

Phase 2

Degenerative Disc Disease

Prochymal™ adult human mesenchymal stem cells

Phase 2

Crohn's Disease

Prochymal®- 8 Million cells/kg

Phase 2

Graft Vs Host Disease

Prochymal® - 2 Million cells/kg

Phase 2

Graft Vs Host Disease

Hyaluronan

Phase 2

Recovery Following Partial Medial Meniscectomy

Prochymal

Phase 2

Graft Versus Host Disease

Lumbar Interbody Fusion with Autograft

Phase 2

Degenerative Disc Disease

Prochymal™

Phase 2

Pulmonary Disease, Chronic Obstructive

Single Dose MPCs Injection

Phase 2

Degenerative Disc Disease

Mesenchymal Precursor Cells (MPC) 25 M

Phase 2

Acute Myocardial Infarction

Mesenchymal Stem Cells

Phase 2

Recovery Following Partial Medial Meniscectomy

MSB-CAR001 Combined With Hyaluronan

Phase 2

Anterior Cruciate Ligament Injury

Chondrogen

Phase 2

Recovery Following Partial Medial Meniscectomy

Mesenchymal Precursor Cells (MPCs)

Phase 2

Diabetic Nephropathy

NeoFuse

Phase 2

Cervical Degenerative Disc Disease

Frequently asked questions

What is in MESOBLAST LTD's drug pipeline?→

CatalystAlert tracks 25 drug candidates in MESOBLAST LTD's (MESO) pipeline across Phase 3, Phase 2. Its lead program is Rexlemestrocel-L + HA mixture (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is MESOBLAST LTD's next FDA catalyst?→

MESOBLAST LTD's (MESO) next tracked catalyst is a Phase 3 readout expected July 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track MESO biotech catalysts?→

Add MESO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MESOBLAST LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply